Regional Angiogenesis with Vascular Endothelial Growth Factor in Peripheral Arterial Disease: A Phase II Randomized, Double-Blind, Controlled Study of Adenoviral Delivery of Vascular Endothelial Growth Factor 121 in Patients with Disabling Intermittent Claudication

Circulation

Volumn 108, Issue 16, 2003, Pages 1933-1938

  Rajagopalan, Sanjay ^a,i,j   Mohler III, Emile R ^b   Lederman, Robert J ^c   Mendelsohn, Farrell O ^d   Saucedo, Jorge F ^e   Goldman, Corey K ^f   Blebea, John ^g   Macko, Jennifer ^h   Kessler, Paul D ^h   Rasmussen, Henrik S ^h   Annex, Brian H ⁱ  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Baptist Princeton Medical Center   (United States)

^e University of Oklahoma Medical Center   (United States)

^f Oschner Clinic   (United States)

^g PENNSYLVANIA STATE UNIVERSITY   (United States)

^h GENVEC INC   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j Women's Hospital   (United States)

more..

Author keywords

Angiogenesis; Claudication; Gene therapy; Peripheral vascular disease; Viruses

Indexed keywords

ADENOVIRUS VECTOR; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE TRANSFER; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; REVASCULARIZATION; STROKE; TREADMILL; ADENOVIRUS; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; EDEMA; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; STATISTICS; TREATMENT OUTCOME; WALKING;

ADENOVIRIDAE; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EDEMA; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERMITTENT CLAUDICATION; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WALKING;

EID: 0142023866     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000093398.16124.29     Document Type: Article

References (25)

1. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103: 1231-1236.
2. 121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation. 2000;102:565-571.
3. Mack CA, Magovern CJ, Budenbender KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg. 1998;27:699-709.
4. Rajagopalan S, Trachtenberg J, Mohler E, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol. 2002;90:512-516.
5. Mohler ER III, Rajagopalan S, Olin JW, et al. Adenoviral mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc Med. 2003;8:9-13.
6. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999;100:468-474.
7. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999;230:466-470; discussion 470-472.
8. Gardner AW, Skinner JS, Cantwell BW, et al. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23:402-408.
9. Rajagopalan S, Mohler E III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J. 2003;145:1114-1118.
10. Anonymous. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:786-806.
11. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation. 2000;102:e73-e86.
12. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication; results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98: 678-686.
13. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267-274; discussion 274-275.
14. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618-1624.
15. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359: 2053-2058.
16. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat Med. 2000;6:1102-1103.
17. Dor Y, Djonov V, Abramovitch R, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002;21:1939-1947.
18. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 2003;9:694-701.
19. 121. Gene Ther. In press.
20. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA. 1997;94:3352-3356.
21. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for Coxsackie B viruses and adenoviruses. J Virol. 1998;72: 415-419.
22. Thirion C, Larochelle N, Volpers C, et al. Strategies for muscle-specific targeting of adenoviral gene transfer vectors. Neuromuscul Disord. 2002; 12:S30-S39.
23. O'Hara AJ, Howell JM, Taplin RH, et al. The spread of transgene expression at the site of gene construct injection. Muscle Nerve. 2001; 24:488-495.
24. Communal C, Huq F, Lebeche D, et al. Decreased efficiency of adenovirus-mediated gene transfer in aging cardiomyocytes. Circulation. 2003; 107:1170-1175.
25. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359-1365.